At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 246 enrolled
Drug / intervention
Rituximab-HDS +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicentric Randomized Phase III Study Comparing High Doses of Chemotherapy With Rituximab Followed by Auto-transplant HPC Versus CHOP Plus Rituximab as First Line Therapy in High Risk Patients With DLBCL Non-Hodgkin's Lymphomas
Gruppo Italiano Terapie Innovative nei Linfomi·interventional·Posted Jul 21, 2006·Updated Aug 10, 2017
In Brief
A Phase 3 clinical trial evaluating Rituximab-HDS and Rituximab-CHOP for Diffuse Large B-Cell Lymphoma. Completed, enrolled 246 participants across 16 sites.
Detailed Summary
Multicentric randomized phase III study comparing high doses of chemotherapy with Rituximab followed by auto-transplant HPC versus CHOP plus Rituximab as first line therapy in high risk patients with DLBCL Non-Hodgkin's lymphomas.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Large B-Cell Lymphoma
CountriesItaly
Collaborators--
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2005
First PostedJul 2006
Primary CompletionMar 2013
TodayJul 2026
First PostedJul 21, 2006
Enrollment StartMay 1, 2005
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 19.9 years ago
Interventions
Rituximab-HDSdrug
Rituximab-HDS
Rituximab-CHOPdrug
Rituximab-CHOP